BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 22, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lomitapide: Interim Phase III data

Interim data from 10 evaluable patients treated for at least 6 months in an ongoing, open-label Phase III trial showed that lomitapide titrated up to 60 mg/day reduced mean LDL-C by 44%....

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >